Performance of Advanced Practice Providers compared with that of Physicians in Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules and Superficial Neck Masses.

Advanced practice providers (APPs) perform ultrasound (US)-guided fine-needle aspiration (FNA) procedures for superficial neck lesions after appropriate training in some interventional radiology practices. This allows physicians additional time to be involved in more complex procedures. This report compared the performance between physicians and APPs. This observational retrospective study analyzed data obtained from October 2017 to December 2019. A total of 309 patients underwent US-guided FNA biopsies for superficial neck lesions. The positive diagnostic rates of FNA biopsies were evaluated for both groups. APPs and physicians performed 212 (68.6%) and 97 (31.4%) FNAs, respectively. Biopsies considered diagnostic for the APP and physician groups were 195 (92.0%) and 86 (88.7%), respectively (P = .345). There was no statistically significant difference in diagnostic rates between the 2 types of providers when performing US-guided FNA for superficial neck lesions.

Coexisting intrarenal arteriovenous and caliceovenous fistulae after percutaneous nephrolithotomy: Case report and literature review.

A 58-year-old man was re-admitted to the Urology service with delayed gross hematuria and unstable he-modynamics, following a percutaneous nephrolithotomy (PCNL) procedure performed for an obstructive solitary left lower calyceal stone. A selective left renal angiogram demonstrated an interpolar arteriovenous fistula (AVF), which was treated with successful coil embolization of a sub-segmental feeding branch. Sub-sequent nephrostogram confirmed a coexisting caliceovenous fistula, which was observed and healed spon-taneously. Iatrogenic coexisting intrarenal AVF and caliceovenous fistulae have never been reported and should be considered as a possible cause of delayed severe hematuria with unstable hemodynamics, and/or increase in baseline creatinine after PCNL.

Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy.

PURPOSE: To determine the incidence of wound dehiscence or failure to heal after port placement in patients receiving bevacizumab therapy. A hypothesis was tested that the mean interval between bevacizumab administration and port placement was shorter in patients who had dehiscence than in those who did not. MATERIALS AND METHODS: Medical records of all patients who had venous access ports placed from July 2006 through December 2007 were retrospectively reviewed. A total of 195 ports were placed in 189 patients (106 men) who were treated with bevacizumab within 120 days of port placement. The incidence of wound dehiscence and the significance of dose timing relative to port placement in these patients were calculated. RESULTS: Six of 195 ports (3.1%) were associated with wound dehiscence requiring port removal. The mean interval between bevacizumab dosing and port placement in patients without dehiscence (n = 189) was 16.9 days. The mean interval in patients with dehiscence (n = 6) was 10.8 days. A two-tailed Wilcoxon test was performed, which yielded a P value of .0150. A statistically significant difference in the mean interval between bevacizumab dosing and port placement exists between patients with dehiscence and those without. CONCLUSIONS: Wound dehiscence after port placement was related to timing of bevacizumab therapy. Patients receiving bevacizumab within 10 days of port placement had a higher incidence of wound dehiscence.